PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: PIPELINE LANDSCAPE PART 08: MARKET SEGMENTATION BY MOLECULE TYPE • Segmentation by molecule type • Comparison by molecule type • Biologicals – Market size and forecast 2017-2022 • Small molecules – Market size and forecast 2017-2022 Market opportunity by molecule type PART 09: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 10: CUSTOMER LANDSCAPE PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Increasing patient support programs • Strategic alliances • Advanced technologies PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR LANDSCAPE • Vendors covered • Vendor classification • Market positioning of vendors • Bayer • Biogen • F. Hoffmann-La Roche • Gilead • Merck PART 16: APPENDIX • List of abbreviations     Exhibit 01: Parent market Exhibit 02: Global NHL therapeutics market segmentation Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition: Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global follicular lymphoma therapeutics market – Market size and forecast 2017-2022 ($ mn) Exhibit 09: Global follicular lymphoma therapeutics market – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition: Five forces 2017 Exhibit 18: Pipeline landscape by development phase Exhibit 19: Late stage pipeline molecules for the treatment of follicular lymphoma Exhibit 20: Global follicular lymphoma therapeutics market – Market share by molecule type 2017-2022 (%) Exhibit 21: Comparison by molecule type Exhibit 22: Global follicular lymphoma therapeutics market by biologicals – Market size and forecast 2017-2022 ($ mn) Exhibit 23: Global follicular lymphoma therapeutics market by biologicals – Year-over-year growth 2018-2022 (%) Exhibit 24: Global follicular lymphoma therapeutics market by small molecules – Market size and forecast 2017-2022 ($ mn) Exhibit 25: Global follicular lymphoma therapeutics market by small molecules – Year-over-year growth 2018-2022 (%) Exhibit 26: Market opportunity by molecule type Exhibit 27: Global follicular lymphoma therapeutics market – Market share by geography 2017-2022 (%) Exhibit 28: Regional comparison Exhibit 29: Follicular lymphoma therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 30: Follicular lymphoma therapeutics market in Americas – Year-over-year growth 2018-2022 (%) Exhibit 31: Top 3 countries in Americas Exhibit 32: Follicular lymphoma therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 33: Follicular lymphoma therapeutics market in EMEA – Year-over-year growth 2018-2022 (%) Exhibit 34: Top 3 countries in EMEA Exhibit 35: Follicular lymphoma therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 36: Follicular lymphoma therapeutics market in APAC – Year-over-year growth 2018-2022 (%) Exhibit 37: Top 3 countries in APAC Exhibit 38: Market opportunity Exhibit 39: Customer landscape Exhibit 40: Vendor landscape Exhibit 41: Landscape disruption Exhibit 42: Vendors covered Exhibit 43: Vendor classification Exhibit 44: Market positioning of vendors Exhibit 45: Bayer – Overview Exhibit 46: Bayer – Business segments Exhibit 47: Bayer – Organizational developments Exhibit 48: Bayer – Geographic focus Exhibit 49: Bayer – Segment focus Exhibit 50: Bayer – Key offerings Exhibit 51: Bayer – Key customers Exhibit 52: Biogen – Overview Exhibit 53: Biogen – Business segments Exhibit 54: Biogen – Organizational developments Exhibit 55: Biogen – Geographic focus Exhibit 56: Biogen – Key offerings Exhibit 57: Biogen – Key customers Exhibit 58: F. Hoffmann-La Roche – Overview Exhibit 59: F. Hoffmann-La Roche – Business segments Exhibit 60: F. Hoffmann-La Roche – Organizational developments Exhibit 61: F. Hoffmann-La Roche – Geographic focus Exhibit 62: F. Hoffmann-La Roche – Segment focus Exhibit 63: F. Hoffmann-La Roche – Key offerings Exhibit 64: F. Hoffmann-La Roche – Key customers Exhibit 65: Gilead – Overview Exhibit 66: Gilead – Business segments Exhibit 67: Gilead – Organizational developments Exhibit 68: Gilead – Geographic focus Exhibit 69: Gilead – Key offerings Exhibit 70: Gilead – Key customers Exhibit 71: Merck – Overview Exhibit 72: Merck – Business segments Exhibit 73: Merck – Organizational developments Exhibit 74: Merck – Geographic focus Exhibit 75: Merck – Segment focus Exhibit 76: Merck – Key offerings Exhibit 77: Merck – Key customers

Bayer Biogen F. Hoffmann-La Roche Gilead Merck